Back to results
US 2026/0092310 A1Published application
Cas12a compositions and methods
AssigneeNew England Biolabs, Inc.
InventorsJuan Pan, G. Brett Robb, Nathan Tanner, Ivan R. Correa, JR.
Life of this patent
Estimating the term…
Abstract
The present disclosure relates, in some embodiments to compositions comprising a variant Cas12a and one-pot methods of using a variant Cas12a with amplification to detect a sequence of interest.
Claims25
A composition comprising:
- a variant Cas12a having an amino acid sequence at least 90% identical to one or more of SEQ ID NOS:
- 1-16, wherein the variant Cas12a has thermostable cis recognition activity and thermostable trans nuclease activity;
- a crRNA operable with the variant Cas12a;
- and
- optionally, a non-naturally occurring buffer.
2 more elements
A one-pot method comprising contacting at a single temperature and in a single container:
- a variant Cas12a having an amino acid sequence at least 90% identical to one or more of SEQ ID NOS:
- 1-16, wherein the variant Cas12a has thermostable cis recognition activity and thermostable trans nuclease activity;
- a crRNA operable with the variant Cas12a, wherein the molar ratio of variant Cas12a:
- crRNA is optionally 1:1 to 1:20;
- a polynucleotide comprising a nucleic acid sequence of interest;
- amplification primers complementary to at least a portion of the sequence of interest and operable to support amplification of the sequence of interest;
- optionally, a reverse transcriptase;
- a DNA polymerase;
- a trans nuclease substrate;
- and
- optionally, a non-naturally occurring buffer.
8 more elements
A variant Cas12a having an amino acid sequence at least 90% identical to one or more of SEQ ID NOS:
- 1-16, wherein the variant Cas12a has thermostable cis recognition activity and thermostable trans nuclease activity.
Dependencies are inferred from the claim text.